This is the point I have made over some time: there is no evidence whatsoever that BIT225 has any effect in treatment non-responders, and no particular reason to suspect that it would. To prove it either way will require a new series of trials, sufficiently expensive to absolutely require support from a larger company, and given that current or nearly available treatments give 97-98% cure, is a market of 2-3% of first world HCV actually large enough to be commercially viable. Back in 2012 I asked this company about what their reaction was to sofosbuvir, and got the response "the market is big enough for other drugs", followed by 4 years of further trials with PEG-riba when that combination was clearly dead in the water. This company has been way too slow on its feet.
- Forums
- ASX - By Stock
- BIT
- Thoughts
Thoughts, page-17
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.0¢ |
Change
-0.001(3.23%) |
Mkt cap ! $27.06M |
Open | High | Low | Value | Volume |
3.1¢ | 3.2¢ | 3.0¢ | $4.624K | 149.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 919909 | 3.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.1¢ | 12195 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 919909 | 0.030 |
4 | 1012888 | 0.029 |
3 | 218000 | 0.028 |
2 | 137000 | 0.027 |
3 | 3104559 | 0.026 |
Price($) | Vol. | No. |
---|---|---|
0.031 | 12195 | 1 |
0.033 | 100000 | 1 |
0.034 | 100000 | 1 |
0.035 | 299251 | 4 |
0.037 | 537816 | 2 |
Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |